Abivax (ABVX) Stock Analysis & Forecast

Nov 13 close

$87.58−2.62 (−2.9%)

Gekko Brief

AI summaryNov 9 close

Abivax shares have declined 31.2% over the last three months and remain below their 20-day, 50-day, and 200-day moving averages, reflecting a continued bearish configuration despite a modest midday rebound this week. The stock has also been cited among the better performers in the SBF 120 after an earlier quarterly drop of nearly 24%, and the company has confirmed its participation in a series of fall investor conferences running from 9 November through 3 December, including a presentation in Frankfurt on 23 November.

Abivax closed at $87.00, up 1.5% on the day, but sits well below its 50-day average of $96.67 and 200-day average of $113.11, with the 50-day itself below the 200-day. The GekkoIndex reads 61.2, placing the stock in the Accumulation zone, while the price remains 23.1% below the Gekko Fair Value of $113.08.

The next earnings report is scheduled for 21 December 2026, 41 days out, placing it outside a typical 20-trading-day holding window; the prior report on 21 September showed an actual loss of $1.71 per share against an estimate of -$1.03, with a reaction of -6.4%. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over the past three years shows a mean 20-day return of -3.5%, with gains in only 1 of those periods, a pattern worth noting alongside the upcoming investor conference schedule.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Abivax price vs fair value

$112.05$87.58Nov ’25May ’26Nov ’26
Close $87.58200-day averageGekko Fair Value $112.05

Abivax quick facts

Market cap
$7.52B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$6.08
Revenue, TTM
$4.67M
Profit margin
0%
Dividend yield
—
Beta
-0.33
Volume
587,853 avg 809,426
1-year return
−15.3%
Typical daily move
±4.3%
Typical 20-day move
±10.8%
50-day average
$94.85
200-day average
$112.57
Next earnings
Dec 21
Shares outstanding
87.54M
52-week range
$69.81$148.83

Abivax swing-trade checklist

Abivax scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive0 mixed2 headwinds

  • Trendheadwind

    Below 50 and 200-day

    Close $87.58 is below the 50-day ($94.85) and 200-day ($112.57) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    60.3, Accumulation

    Reading 60.3 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    21.8% below

    Price is 21.8% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 36 days

    Next report Dec 21, 2026, 36 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −7.2% on average

    From this point in the calendar, the next 20 trading days averaged −7.2% over 3 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Abivax stock chart and price history

Abivax closed at $87.58 on Nov 13, 2026, −15.3% over the past year, inside a 52-week range of $69.81 to $148.83.

Close50-day average200-day averageVolume
Abivax share price, past year, with 50-day and 200-day moving averages and volume$40$60$80$100$120$140DecJan 2026FebMarAprMayJunJulAugSepOctNov87.58

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−5.2%
3 months
−27.5%
6 months
−23.5%
1 year
−15.3%
The full ABVX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ABVX in Gekko

Follow Abivax through every session

Put ABVX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ABVX in GekkoFree for 7 days. No credit card required.

About Abivax

Abivax works on developing drug candidates aimed at inflammatory, infectious, and oncological conditions. Its most advanced program centers on a compound called ABX464, which has been studied for ulcerative colitis, Crohn's Disease, and COVID-19, with additional testing in rheumatoid arthritis and earlier work showing viral remission results in HIV patients. The company is also progressing a second candidate, ABX 196, designed to stimulate immune response, in trials targeting hepatocellular cancer.

Beyond its core pipeline, Abivax runs research programs directed at Dengue fever, influenza, and respiratory syncytial virus. Its work is supported by license arrangements with French research institutions, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie, connecting its drug development efforts to established scientific bodies.

Abivax was established in 2013 and is headquartered in Paris, France. Its shares trade under the ticker ABVX.

Sector
Health technology
Website
abivax.com

Abivax GekkoIndex: the smart money zone

Abivax’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.3, in the Accumulation zone, down 2.6 points over five sessions.

010060.3Accumulation

Down 2.6 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying46+2.2%+1.5%+1.9%−11.3%
Accumulation (current zone)265Not available
Neutral295−1.6%−1.8%+20.0%+58.2%
Distribution44Not available
Selling5Too few readings yet

Average ABVX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the ABVX price, zone by zone.Track ABVX in Gekko

Is Abivax stock overvalued? Gekko Fair Value

Abivax trades 21.8% below Gekko Fair Value of $112.05, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Abivax shares are worth, recalculated every trading day.

$112.05

Gekko Fair Value, Nov 14, 2026

21.8% Undervalued

At the end of Aug 2026 the price was 26.1% below the estimate.

Gekko Fair ValueShare price, month end
$112$88Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ABVX in Gekko

Abivax insider and Congress trading

No open-market insider purchases were filed for Abivax, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ABVX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ABVX insider filing, plotted on the chart in Gekko.Open ABVX in Gekko

Congress trades last 90 days

No trades in ABVX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ABVX, plotted on the chart in Gekko.Open ABVX in Gekko

Hedge funds and billionaires quarter ended Sep 30

1of the funds Gekko tracks holds ABVX.

1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Abivax earnings: next date and track record

Abivax reports on Dec 21, 2026 (36 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±8.2%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−6.7%Nov ’24−0.5%Mar ’25+28.6%Jun ’25+1.4%Sep ’25−11.6%Dec ’25−8.5%Mar ’26+1.9%May ’26−6.4%Sep ’26
ReportedEPSSurpriseRevenueSurpriseMove
Sep 21, 2026−$1.71
est −$1.03
−66.1%$1.37M
est $799K
+72.0%−6.4%
May 22, 2026−$0.71
est −$0.81
+12.3%$1.51M
est $401K
+277.3%+1.9%
Mar 23, 2026−$1.18
est −$1.04
−13.5%$515K
est $1.80M
−71.4%−8.5%
Dec 15, 2025−$2.47
est −$0.79
−212.7%$2.40M
est $1.35M
+78.5%−11.6%
Sep 8, 2025−$0.89
est −$0.95
+6.3%$1.33M
est $1.35M
−1.4%+1.4%
Jun 2, 2025−$0.95
est −$0.76
−25.0%$1.16M
est $3.35M
−65.3%+28.6%
Mar 24, 2025−$0.81
est −$1.29
+36.9%$6.37M
est $2.83M
+125.0%−0.5%
Nov 14, 2024−$0.70
est −$0.70
+0.3%—
est $3.59M
—−6.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Abivax stock forecast and analyst price targets

Analysts’ average 12-month price target for Abivax is $163.58, +86.8% from the last close, from 8 firms rating the stock in the last 90 days.

$163.58consensus 12-month target, +86.8% from the last close
Low $118High $180
Buy7
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 8 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 21Piper SandlerBuy, maintained$175+99.8%
Oct 20BarclaysBuy, maintained$148+69.0%
Oct 20GuggenheimBuy, reiterated$175+99.8%
Oct 1BTIGBuy, reiterated$175+99.8%
Sep 28Morgan StanleyBuy, maintained$180+105.5%
−7.2%average move over the next 20 trading days in the last 3 years
±4.3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Abivax seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Abivax averaged −7.2% across the last 3 years, rising in 1 of them.

Next 20 trading days, by year

−3.6%2023−28.6%2024+6.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.2%1 of 3
Next 10 trading days−4.9%1 of 3
Next 15 trading days−6.5%1 of 3
Next 20 trading days−7.2%1 of 3
Next 30 trading days−1.6%1 of 3

For scale, ABVX’s typical 20-trading-day move in either direction is about 10.8%.

Abivax market cap and key statistics

Abivax’s market cap is $7.52B and revenue of $4.67M over the last twelve months.

Valuation

Market cap
$7.52B
EPS, TTM
−$6.08
Gekko Fair Value
$112.05

Trading

Volume
587,853
Avg volume, 20 days
809,426
52-week high
$148.83
52-week low
$69.81
Shares outstanding
87.54M

Financials

Revenue, TTM
$4.67M
Profit margin
0%
Return on equity
-252.3%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
-0.33
Typical daily move
±4.3%
Typical 20-day move
±10.8%

Abivax stock news this week

Coverage of Abivax this week reads positive: 3 positive, 3 neutral and 2 negative headlines.

News sentiment positive

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health technology

Abivax stock FAQ

What is Abivax’s market cap?

Abivax’s market cap is $7.52B at the Nov 13, 2026 close of $87.58, with 87.54M shares outstanding.

What is the Abivax stock forecast?

The consensus analyst 12-month price target for Abivax is $163.58, +86.8% from the last close. Of the 8 firms that rated the stock in the last 90 days, 7 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Abivax stock overvalued or undervalued?

On Gekko’s estimate Abivax is undervalued: the Nov 13, 2026 close of $87.58 is 21.8% below Gekko Fair Value of $112.05. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Abivax report earnings next?

Abivax is expected to report on Dec 21, 2026 (36 days away). Analysts expect earnings of −$0.92 per share on revenue of $923K. Abivax beat the earnings estimate in 4 of its last 8 reports, moving 8.2% on average across the report.

What is Abivax’s 52-week high and low?

Abivax’s 52-week high is $148.83 and its 52-week low is $69.81; it closed at $87.58 on Nov 13, 2026, −15.3% over the past year.

Is Abivax stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Abivax the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.